# A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants.

> **NCT07724431** · PHASE1 · NOT_YET_RECRUITING · sponsor: **HongKong Curegene Innovation Co., Limited** · enrollment: 64 (estimated)

## Conditions studied

- Overweight and Obesity

## Interventions

- **DRUG:** CG-0416

## Key facts

- **NCT ID:** NCT07724431
- **Lead sponsor:** HongKong Curegene Innovation Co., Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-03
- **Final completion:** 2027-04
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724431, "A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07724431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*